Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lenipsor+ is a topical dermocosmetic and medical device developed by the Italian biotech startup iDelivery for the management of psoriasis. The product is formulated as a gel containing a patented phyto-complex extract derived from *Daphne laureola*. It is designed to improve the appearance of skin affected by desquamation, plaques, and erythema typical of psoriatic dermatitis. The treatment leverages iDelivery's specialized nanocarrier delivery systems to enhance the efficacy of its natural active ingredients. Clinical evaluation includes in vitro and in vivo testing on over 200 patients, and the product is protected by international patents in Europe, the USA, Canada, and Japan. It is positioned as a low-cost topical solution for psoriatic plaques.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lenipsor+.